Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 756 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Glaucoma, Ocular Hypertension
Interventions: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions: Nicotinamide, Standard Glaucoma Therapy; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Open Angle Glaucoma, Open Angle Glaucoma
Interventions: Minimally Invasive Micro Sclerostomy Device; Device
Lead sponsor: Sanoculis Ltd; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glaucoma, Open Angle Glaucoma, Ocular Hypertension
Interventions: PhXA41, timolol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1994
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Gainesville, Florida + 12 more

Conditions: Glaucoma, Glaucoma Open-Angle
Interventions: Eyetronic rtACS, Sham rtACS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Interventions: VISUAL FIELD TESTING; Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Alcon Investigational Agent; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Healthy
Interventions: Variation in eye pressure response to timolol and latanoprost treatment; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years and older
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Omaha, Nebraska

Conditions: Glaucoma, Primary Open Angle, Ocular Hypertension
Interventions: WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Primary Open Angle Glaucoma
Interventions: Placement of the sponge, Mitomycin-C; Procedure · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide/Timolol; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma
Interventions: Selective laser trabeculoplasty; Procedure
Lead sponsor: West Virginia University; Other
Eligibility: 30 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Glaucoma, Open-Angle, Chronic Wounds
Interventions: Timolol Maleate; Drug
Lead sponsor: VA Northern California Health Care System; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mather, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 51
States / cities: Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more

Conditions: Glaucoma
Interventions: Timolol, latanoprost; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 36 Weeks to 18 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Pembroke Pines, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more

Conditions: Glaucoma
Interventions: Surgery, Selective Laser Trabeculoplasty; Procedure
Lead sponsor: University of Kentucky; Other
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Glaucoma, Open-Angle, Eye Diseases
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Medication Adherence, Glaucoma
Interventions: eyeGuide; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Glaucoma
Interventions: Rocklatan, Systane Ultra; Drug
Lead sponsor: Colorado Ophthalmology Associates PC; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Timeline: 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cataracts, Glaucoma, Myopia
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 45 Years and older
Enrollment: 7,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2020
U.S. locations: 5
States / cities: Baltimore, Maryland • Bethesda, Maryland • Boston, Massachusetts + 2 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution 0.02%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more

Search by objective public record fields.

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension

Electrical Stimulation for Vision Neuroenhancement in Glaucoma

Evaluating iCare COMPASS as a Visual Field Diagnostic Tool

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

Glaucoma Biomarkers

Safety and IOP-Lowering Effects of WB007

The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty

Absorption and Safety of Topical Timolol to Treat Chronic Wounds

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

Effects of Selective Laser Trabeculoplasty

The Flashing Light-Induced Pupil Response (FLIPR) Glaucoma Study

The eyeGuide: Improving Glaucoma Self-management With a Personalized Behavior Change Program

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment

Family Studies of Eye Traits

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting